For the Inventor, By the Inventor

Enter assignee name

Research Triangle Park, NC, United States of America

G1 Therapeutics, Inc.

USPTO Granted Patents = 48

% Expired Patents = 8.3

CIPO Patents = 18

EPO Patents = 8

Trademarks = 6

Forward Citations = 624

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Jay Copeland Strum (41 out of 56 patents)

Francis Xavier Tavares (28 out of 47 patents)

Patrick Joseph Roberts (18 out of 25 patents)

4. John Emerson Bisi (18 out of 23 patents)

5. Hannah S White (7 out of 13 patents)

6. Jessica A Sorrentino (5 out of 8 patents)

7. Alexander Smith (5 out of 17 patents)

8. Robert C Gadwood (3 out of 34 patents)

9. Ricky D Gaston (3 out of 3 patents)

10. Stephen E Schneider (3 out of 11 patents)

11. Andrew Beelen (2 out of 3 patents)

12. Jaroslaw Mazurek (2 out of 5 patents)

13. Sergiy Krasutsky (2 out of 5 patents)

14. Jian-Xie Chen (2 out of 2 patents)

15. Roberta L Dorrow (2 out of 2 patents)

Core Competencies:

Trilaciclib

CDK Inhibitors

HSPC-Sparing Treatments

Cancer Therapy

Anti-Neoplastic Combinations

Pyrimidine-Based Compounds

Cyclin-Dependent Kinases

Transient Protection

Combination Therapy

Renal Tissue Protection

Dosing Regimens

Lactam Kinase Inhibitors

48 patents: Sort by Forward Citations

1. 12168666 - Morphic forms of trilaciclib and methods of manufacture thereof (2024-12-17),

2. 12139494 - Morphic forms of G1T38 and methods of manufacture thereof (2024-11-12),

3. 11717523 - Transient protection of normal cells during chemotherapy (2023-08-08),

4. 11708337 - Synthesis of 1,4-diazaspiro[5.5]undecan-3-one (2023-07-25),

5. 11654148 - HSPC-sparing treatments for RB-positive abnormal cellular proliferation (2023-05-23),

6. 11643416 - Substituted 1',2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors (2023-05-09),

7. 11629150 - Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines (2023-04-18),

8. 11529352 - Preservation of immune response during chemotherapy regimens (2022-12-20),

9. 11446295 - Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors (2022-09-20),

10. 11395821 - Treatment of EGFR-driven cancer with fewer side effects (2022-07-26),

11. 11364222 - Combination therapy for treatment of cancer (2022-06-21),

12. 11357779 - G1T38 superior dosage regimes (2022-06-14),

13. 11090306 - Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors (2021-08-17),

14. 11040042 - Transient protection of normal cells during chemotherapy (2021-06-22),

15. 10988479 - Morphic forms of trilaciclib and methods of manufacture thereof (2021-04-27),

Company Overview

G1 Therapeutics, Inc. is a biotechnology company based in Research Triangle Park, NC, focused on developing innovative therapies to improve outcomes for cancer patients. The company specializes in novel treatments such as Trilaciclib and G1T38, which aim to enhance chemotherapy efficacy while minimizing side effects. G1 Therapeutics is dedicated to advancing CDK inhibitors and HSPC-sparing treatments, leveraging its expertise in anti-neoplastic combinations and pyrimidine-based compounds to provide transient protection during cancer treatment.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

48 Patents

#12 in Research Triangle Park, NC

#178 in North Carolina

#7,280 in US

#14,536 in the World

Research Triangle Park, NC, United States of America

G1 Therapeutics, Inc.

Forward Citations = 624

36 inventors:

Jay Copeland Strum (41 out of 56 patents)

Francis Xavier Tavares (28 out of 47 patents)

Patrick Joseph Roberts (18 out of 25 patents)

4. John Emerson Bisi (18 out of 23 patents)

5. Hannah S White (7 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: G1 Therapeutics, Inc.. Retrieved from https://idiyas.com/company/g1-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…